Group 1 - UCB SA's shares surged to a record high, increasing market value by over €7 billion ($8.2 billion) after MoonLake Immunotherapeutics announced disappointing late-stage trial results for its drug sonelokimab [1][2] - MoonLake's sonelokimab showed a combined efficacy of only 14% on a placebo-adjusted basis, while UCB's Bimzelx demonstrated an 18% benefit, indicating a clear superiority of UCB's treatment [2][3] - UCB's market value now exceeds €44 billion, while MoonLake's capitalization has dropped to approximately $435 million following the trial data announcement [6] Group 2 - UCB's Bimzelx has seen a significant increase in value, soaring roughly 190% since late 2023 when it was approved in the US for psoriasis treatment, and it has also been approved for hidradenitis suppurativa [4] - Hidradenitis suppurativa represents a crucial growth area for UCB, accounting for 21% of Bimzelx's global net sales in the first half of 2025, with the market projected to grow to $15 billion by 2035 from the current $2 billion [5]